| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8477668 | Molecular and Cellular Endocrinology | 2012 | 9 Pages |
Abstract
⺠5-ARIs reduce risk of being diagnosed with prostate cancer but they do not eliminate it. ⺠Castration remains the frontline treatment for metastatic prostate cancer. ⺠Neoadjuvant endocrine treatment has its place mainly in the external beam radiotherapy setting. ⺠IAD is as effective as continuous ADT in non-metastatic, locally advanced prostate cancer. ⺠The decision regarding the type of androgen deprivation should be made individually.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Teuvo L.J. Tammela,